ASX Blue-Chip Stocks Plunge $60B in Value Over 12 Months, June 11

Four former ASX heavyweight stocks have collapsed into the worst-performing tier of the Australian sharemarket. CSL, Cochlear, WiseTech and Xero have shed $60 billion in combined market capitalisation over the past 12 months, with shares down around 60%. These companies were among the 50 largest on the ASX just one year ago. The sharp decline has hit large-cap investors hard and raised questions about sector concentration risk in Australia’s market.

How Far the Giants Have Fallen

CSL, Cochlear, WiseTech and Xero were once pillars of the Australian sharemarket. Today they rank among the ASX’s worst performers. Together they have lost $60 billion in market value over 12 months, with share prices down roughly 60%. The scale of the decline is unusual for companies of this size and profile. Large-cap investors who held these stocks have seen substantial losses, with returns dragged down by the concentrated weight these names carry in the index.

Sector Concentration Weighs on the Broader Market

The ASX 200 remains heavily influenced by a handful of sector leaders. When major players stumble, their weight in the index can drag down overall market performance. Rio Tinto fell 1.81% to A$179.44 on Tuesday, extending recent weakness in mining stocks. Goodman Group, the ASX’s largest real estate investment trust by market cap, closed 0.32% higher at A$31.20. Semiconductor volatility has also hit global markets, with the Nasdaq Composite flipping negative as chip stocks swung wildly.

What This Means for Investors

With Meyka rating Rio Tinto (RIO.AX) a B+ and targeting A$153.50 in 12 months, the data shows mixed signals for large-cap exposure. The ASX 200 closed up 0.6% to 8,653 points on Tuesday, but the concentration of losses in former blue-chips highlights the risk of portfolio concentration. Investors holding these fallen giants face a choice: wait for a recovery or reassess their allocation to large-cap Australian stocks.

Final Thoughts

Four former ASX blue-chips have lost $60 billion and fallen 60% in 12 months, now ranking among the worst performers. The sharp decline reflects both company-specific challenges and sector concentration risk in Australia’s market. Investors should review their large-cap exposure carefully.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.